Bispecific agents: the future of AML and MDS treatment?
A "chemo-sparing" MRD-driven strategy for CLL
EBMT 2018: Investigating breakthrough therapies for treating AML in adults
How is the landscape of Hodgkin lymphoma therapy changing?
Advancements in AML therapy at ASH 2017